Next-generation targeted MRI contrast agents for better cancer imaging
Official title: Development of next-generation targeted MRI contrast agents
Funded at Molecular Theranostics, LLC · NIH-11226020 · Data updated 2026-11-12
This grant aims to create safer, more effective MRI contrast agents that can help detect and diagnose cancer more accurately.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Molecular Theranostics, LLC NIH-funded |
| Lab location | 1 site (Beachwood, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $528,259 |
| NIH project number | 1R01CA297667-01A1 |
| Project ID | NIH-11226020 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with solid tumors undergoing MRI evaluation for cancer diagnosis or management.
✕Less likely to help
Patients without cancer or those not undergoing MRI could see little immediate benefit from this research.
What this research studies
This project develops advanced MRI contrast agents that actively target tumor tissue to improve image clarity and diagnostic confidence for cancer patients. It builds on first-in-class agents and explores non-gadolinium options to reduce safety concerns while preserving high image quality. Researchers will design, test, and optimize new compounds that enhance MRI signals specifically in tumors, potentially enabling earlier and more precise treatment decisions.
Why it matters
Potential benefit: If successful, patients could benefit from clearer cancer images with fewer safety risks, leading to better treatment planning.
How similar studies have gone: Preclinical and early clinical data suggest targeted MRI agents can improve tumor imaging, with ongoing work to optimize safety and efficacy.
Where this research is happening
-
Molecular Theranostics, LLC
Beachwood, United States Active
Researchers
- Principal investigator: Hall, Ryan Christopher — Molecular Theranostics, LLC
- Study coordinator: Hall, Ryan Christopher
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.